Join to access to all OVN content. Join for Free
Professional Development: Why Consider an Executive Coach
Life Reset Labs Dana Paskalis coaching in professional development career coaching executive coach advice

Professional Development: Why Consider an Executive Coach


Share This Article


Summary

In this episode, Dana Paskalis, founder of Life Reset Labs, joins to discuss the pivotal role of coaching in personal and professional development. Dana outlines her career path leading to the creation of her coaching company and highlights the significance of self-talk and mindset in advancing one's career. She explores the differences between a mentor and a coach, offering advice on when to seek professional guidance. The conversation also covers the impact of company culture and handling layoffs, alongside strategies for proactive career planning. The episode concludes with a reminder to subscribe for more insights.

Today’s guest is Dana Paskalis, CEO and Founder of Life Reset Labs and we discuss why professionals should consider an executive or career coach
Dana discusses….

πŸ‘‰ What led her to transition to a Certified Coach and Life Strategist
πŸ‘‰ What exactly a Certified Coach and Life Strategist does
πŸ‘‰ What is the difference between a coach and a mentor
πŸ‘‰ Who should consider a coach (and who doesn’t need a coach)
πŸ‘‰ Tips and career advice for MSLs
πŸ‘‰ Tips and advice for finding success in 2023

Click for Source
Life Reset Labs, Dana Paskalis, coaching in professional development, career coaching, executive coach advice

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH

Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Article
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, GaΓ«lle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Article
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

Article
Transforming oncology: Five frontiers driving progress in cancer care
Partner Avatar iNIZIO

Transforming oncology: Five frontiers driving progress in cancer care

Article
Virtual Oncology MSL Team Increases KOL Engagement by 120%
Partner Avatar iNIZIO

Virtual Oncology MSL Team Increases KOL Engagement by 120%

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Explore OVN